Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vishal Goyal

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Clinical and Translational Science|March 15, 2024
Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteersVishal Goyal, Edrich Krantz, Francois Simon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 11, 2022
AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 TrialSakib Burza, Raman Mahajan, Shahwar Kazmi, et al.
Plos Neglected Tropical Diseases|October 23, 2018
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, IndiaVishal Goyal, Raman Mahajan, Krishna Pandey, et al.
The Lancet. Gastroenterology & Hepatology|April 18, 2021
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialIsabelle Andrieux-Meyer, Soek-Siam Tan, Sombat Thanprasertsuk, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Clinical and Translational Science|March 15, 2024
Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteersVishal Goyal, Edrich Krantz, Francois Simon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 11, 2022
AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 TrialSakib Burza, Raman Mahajan, Shahwar Kazmi, et al.
Plos Neglected Tropical Diseases|October 23, 2018
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, IndiaVishal Goyal, Raman Mahajan, Krishna Pandey, et al.
The Lancet. Gastroenterology & Hepatology|April 18, 2021
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialIsabelle Andrieux-Meyer, Soek-Siam Tan, Sombat Thanprasertsuk, et al.
Pageof 4